A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

Clinical trial NCT05567458 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05567458
Sponsor: Bristol-Myers Squibb
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Beta-thalassemia

Start date: 2022-10-17
Primary completion: 2025-08-01
Enrollment: 94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.